BEGIN YOUR JOURNEY TOWARDS PREVENTING CRYPTOGENIC STROKE

If you’ve had a stroke due to an unknown cause, learn how you may be able to prevent another with the Amplatzer™ PFO Occluder.

Current selected region:
UNITED STATES
I'm a patient healthcare professionals
Skip to main content

About the Amplatzer™ PFO Occluder

About device i Stock 930020910

The Amplatzer™ PFO Occluder consists of two nitinol wire mesh discs that can be placed in your heart to close the PFO through a minimally invasive, catheter-based technique. The PFO occluder is designed to stop the blood flow and potential clots through the PFO.

Amplatzer™ PFO Occluder
Occluder stroke risk 2x

Clinical data

The Amplatzer™ PFO Occluder was studied in the RESPECT Trial in the US and Canada. The trial enrolled 980 patients, between the ages of 18 to 60, who were diagnosed with a PFO and a cryptogenic stroke. Patients were randomly assigned to either receive the Amplatzer™ PFO Occluder plus blood-thinning medication, or blood-thinning medication alone. The patients were assessed at 30 days, six months, one year and yearly thereafter. The RESPECT Trial was designed to evaluate whether PFO closure with the Amplatzer™ PFO Occluder plus blood-thinning medication was more effective in reducing the risk of another ischemic stroke compared with the sole use of blood-thinning medication. Over a median follow-up period of 5.9 years, the rate of recurrent ischemic stroke was 45% lower with PFO closure compared to medical management exclusively.²

In the CLOSE Trial, 663 patients received either the Amplatzer™ PFO Occluder or another approved PFO occluder. This trial showed a 97% stroke risk reduction in patients who underwent PFO closure plus antiplatelet therapy compared to patients who received antiplatelets only.¹

Rates of new strokes in the RESPECT trial

The results of the RESPECT Trial analysis, which was conducted when the average follow-up was about five years, suggested that if 1,000 patients were treated with PFO closure, about six of these patients would have a stroke after one year compared to about 10 out of 1,000 patients treated with blood-thinning medication alone. That’s a 45% relative risk reduction of recurrent stroke for patients who had their PFO closed compared to people who just took blood-thinning medication.²

Amplatzer 2x

AS THE PIONEER IN PFO CLOSURE, THE AMPLATZER™ PFO OCCLUDER HAS BEEN USED TO TREAT OVER 130,000 PATIENTS WORLDWIDE³

Clinical data on PFO Closure with the Amplatzer™ PFO Occluder are still being investigated through our Post Approval Study. If you would like to learn more about this exciting study and find out if you are eligible to participate, you can read more about it here.

Read more

What happens after the PFO closure procedure?

Learn about the post-procedure care plan.

Read more

Learn more about the respect trial

Read more about the largest trial with the most extensive patient follow-up of any trial conducted on PFO closure and its impact on the prevention of another ischemic stroke.

The respect trial
References
  1. Mas J-L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017; 377: 1011-21.
  2. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017; 377: 1022-32.
  3. Internal data. Data on-file at Abbott.
MAT-2003145